Attenuation of Neointimal Vascular Smooth Muscle Cellularity in Atheroma by Plasminogen Activator Inhibitor Type 1 (PAI-1)
Departments of Medicine (DJS,MH,HT,MR,BES) and Pathology (MW,DJT), University of Vermont, Burlington, Vermont
Correspondence to: David J. Schneider, MD, University of Vermont, Colchester Research Facility, 208 S. Park Drive, Colchester, VT 05446. E-mail: david.schneider{at}uvm.edu
![]() |
Summary |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
(J Histochem Cytochem 52:10911099, 2004)
Key Words: atherosclerosis plasminogen activators extracellular matrix vascular smooth muscle
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
We have hypothesized that limitation of activation of intramural plasminogen activators by their primary inhibitor, plasminogen activator inhibitor type 1 (PAI-1), is one factor predisposing to evolution of vulnerable plaques by promoting or retarding neointimal migration of VSMCs, leading to a paucity of such cells and consequent elaboration of thin rather than thick fibrous plaques (Sobel 1999; Sobel et al. 2003
). The present study was performed to determine whether decreased migration of VSMCs, characterized in vitro, would ensue if VSMC expression of PAI-1 were increased with the use of the promoter region of the VSMC gene SM-22
. In addition, we determined whether neointimal cellularity would be diminished in vivo by overexpression of VSMC PAI-1 during the evolution of atheroma in apolipoprotein E (ApoE)-deficient mice. A specific objective was to characterize the effect of overexpression of PAI-1 on the evolution of atheroma as opposed to the response to vascular injury. Because a paucity of VSMCs in the neointima contributes to the development of vulnerable plaques, we sought to characterize the impact of VSMC overexpression of PAI-1 on plaque morphology rather than on the size of the atherosclerotic lesion.
We generated transgenic mice in which VSMC expression of PAI-1 was increased with the use of the SM22 promoter (SM22-PAI+). Migration of VSMCs explanted from SM22-PAI-positive and -negative littermates through an artificial basement membrane matrix (Matrigel) was determined in vitro. Neointimal cellularity was quantified in ApoE/ mice that were either positive or negative with respect to the SM22-PAI transgene.
![]() |
Materials and Methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The presence of the transgene was determined with DNA isolated from tail biopsies with the use of slot-blot analysis or the polymerase chain reaction (PCR). Slot-blot membranes were hybridized with a 500-bp fragment of human growth hormone cDNA. PCR was performed with the use of a primer in the PAI-1 cDNA (5'-TGAATGAATTTCCTAGCAGG-3') and a primer in the human growth hormone polyadenylation signal (5'-GAGAAACAGAGGGCAACAG-3') (GIBCO; Grand Island, NY). PCR conditions were as follows: 94C (1 min), 30 cycles 94C (30 sec), 60C (60 sec), 72C (2 min), 72C (10 min).
Animals with the transgene (SM22-PAI founders) were backcrossed into the C57Bl/6 line (Jackson Labs; Bar Harbor, ME). The in vitro comparative analyses were performed with the use of transgene-positive and -negative littermates fed a standard low-fat (0.28% cholesterol) diet. SM22-PAI+ mice that were congenic in the C57Bl/6 line were crossed with ApoE/ mice to generate ApoE/SM22-PAI+ mice. ApoE/ and ApoE/SM22-PAI+ mice were fed a high-fat (20% fat, 1.5% cholesterol, Teklad) diet after weaning. Neointimal composition was characterized in 20-week-old male ApoE/ and ApoE/SM22-PAI+ mice. We elected to study male mice to limit variability that might occur as a result of gender, estrous cycle, or hormonal status.
Isolation of Aortas and VSMCs
Animals were euthanized with an IP injection of sodium pentobarbital. Hearts and aortas were flushed clear of blood by perfused PBS until blanching of the liver was noted and were then fixed in paraformaldehyde. Descending aortas were placed in sterile, cold (4C) Hank's balanced salt solution with 100 µg/ml streptomycin plus 300 U/ml penicillin, freed from adherent fat and connective tissue, cut into 1.0-mm3 pieces, placed on the etched surface of a six-well culture dish, and covered with sterile 22 x 22-mm glass coverslips anchored with sterile silicon grease (Dow Corning high vacuum grease, autoclaved). Explants were cultured in 3 ml/wells in complete medium [Dulbecco's modified Eagle's medium (DMEM) supplemented with 20% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 µg/ml streptomycin (GIBCO)] at 37C in room air supplemented with 10% CO2. Cells were propagated after dispersion with 0.25% trypsin in DMEM with 20% fetal bovine serum, 10 ng/ml epidermal growth factor, 50 U/ml penicillin, 50 µg/ml streptomycin, and 1 x ITS (10 ng/ml insulin, 0.55 ng/ml transferrin, 0.67 µg/ml selenium; GIBCO) at 37C in room air enriched with 10% CO2. Experiments were performed with VSMCs harvested from animals 7.530 weeks of age and were cultured for 38 passages. VSMC phenotype was verified by expression of -smooth muscle actin.
Assessment of Cell Migration
Cell migration in vitro was quantified with a Biocoat insert system (Becton Dickinson; Bedford, MA) with the use of 24-well plates and inserts precoated with Matrigel (Becton Dickinson), an artificial basement membrane matrix that contains basement membrane structural components, enzymes, inhibitors, and growth factors. Inserts contained 12-µm-thick matrix on a polyethylene tetrachloride membrane perforated with 8-µm pores. Matrigel was hydrated with DMEM for 2 hr before cell seeding. Cells were cultured in DMEM with 1% FBS. Rat platelet-derived growth factor-BB (100 ng/ml; Sigma, St Louis, MO) was used as a chemoattractant in the lower chamber. Migration was determined 20 hr after the seeding of 5 x 104 VSMCs/ insert. VSMCs were cultured in DMEM without serum for 24 hr before addition to the chamber. Experiments were performed with fresh DMEM supplemented with 4% FBS. After 20 hr, Matrigel and cells were disrupted with a spatula on the upper aspects of the inserts and removed by aspiration. Cells were fixed in 70% methanol (20C for 20 min), rinsed with PBS, and stained in a solution containing propidium iodide (20 µg/ml) and RNase A (200 µg/ml) (Sigma). Culture membranes were sharply separated from inserts and mounted on glass microscope slides in 50% PBS and glycerol.
The slides were evaluated with a laser scanning cytometer (CompuCyte; Cambridge, MA) (Taatjes et al. 2001). In each case, the entire insert mounted on the slide was scanned with a x20 objective lens with the use of an argon ion laser with an orange/red fluorescence detector. The threshold contour was set based on the orange/red fluorescence intensity, with a minimum area of 10 µm2 required to trigger an event. Scanned cells depicted by points on a scattergram were randomly selected and visually relocated with the microscope component of the laser scanning cytometer to confirm their identity as whole cells rather than cell debris.
Immunohistochemical Analysis
Tissue Processing
Aortic tissue was processed for immunofluorescence essentially as described previously (Taatjes et al. 2000). In brief, the hearts and aortas were excised, placed in freshly prepared 3% formaldehyde (in PBS, pH 7.3), fixed overnight at 4C, placed in plastic embedding cassettes, and rinsed for 1 hr with cold running water. The cassettes were transferred into 5% gelatin (Type A from porcine skin; 300 bloom; Sigma) in distilled water for 2 hr at 42C, followed by infiltration in 10% gelatin in distilled water overnight at 42C, refrigerated for 3 hr (4C) to solidify the gelatin, trimmed rectangularly, and immersed immediately in 3% formaldehyde in PBS for 1 hr at 4C to crosslink and strengthen the gelatin. The capsules were then rinsed twice for 15 min each with PBS before freezing. The hearts were then embedded in OCT medium (Tissue-Tek; Sakura Finetek USA, Torrance, CA) in disposable cryostat embedding molds with the aortic arch side of the heart facing down, frozen by plunging into liquid nitrogen-cooled 2-methyl-butane, and stored at 80C until cryosectioning.
Cryostat Sectioning
The frozen hearts were removed from the embedding molds and attached to a cryostat chuck, flat side (arch side of the heart) down. Sixteen-µm-thick sections were collected from a 300-µm area beginning at the valve leaflets. We evaluated five 16-µm-thick aortic sections from each mouse for each component analyzed by quantitative microscopy.
Immunohistochemical Staining
After being rinsed in PBS containing 1% bovine serum albumin (PBS/BSA), the sections were incubated in 10% normal goat serum for 30 min, followed by an overnight incubation at 4C with a polyclonal rabbit anti-human PAI-1 antibody (courtesy of Drs. Lieve Moons and Desire Collen). After three PBS/BSA rinses, sections were incubated with a Cy5-conjugated goat anti-rabbit secondary antibody for 60 min. After a final rinse with PBS/BSA, a coverslip was applied with the use of 1% n-propyl gallate in 50% glycerol/50% PBS as an anti-fade mounting medium. In control incubations, the sections were incubated with secondary antibody alone (i.e., without primary antibody). VSMCs explanted from SM22-PAI-positive and -negative littermates were cultured on coverslips and stained in the same manner. Specificity of the antibody was confirmed by Western blotting analysis (Figure 1). The rabbit polyclonal antibody recognized both free and complexed PAI-1.
|
Confocal Scanning Laser Microscopy
The stained sections were examined with a Bio-Rad MRC 1024ES confocal scanning laser microscopy system (Bio-Rad Laboratories, Life Sciences Division; Hercules, CA). Immunostaining with PAI-1 antibody was visualized by excitation with the 647-nm wavelength line from a krypton/argon laser. For semiquantitative analysis, all images were captured with a x20 objective lens (0.50 NA) and the following settings: image box size 512 x 512 pixels; laser power 30%; confocal iris 2.5 mm; gain 1250 V; black level 2; low signal, slow scan mode; and Kalman averaging x3. Images were archived on 100 Mbyte Zip disks, and photographic prints made with a Fujix Pictrography 3000 video color printer.
Dual antibody-stained images were acquired with the use of sequential capture mode to avoid potential fluorescence bleed-through between channels. Images were captured in sequential mode in the following manner. The 488-nm laser line was used to excite SYTOX Green fluorescence (to label all cell nuclei for orientation purposes), the 568-nm laser line was used to excite the Alexa 568 fluorescence (indicating staining for -smooth muscle actin antibody) and the 647-nm laser line was used to excite the Cy5 fluorescence (indicating staining with the anti-PAI-1 antibody). The three grayscale images were electronically merged to produce a pseudocolored image in which green depicts cell nuclei, red depicts PAI-1 immunoreactivity, and blue depicts smooth muscle actin staining.
Quantitative Analysis of PAI-1 Immunoreactivity
Analyses were performed by personnel who were blinded with respect to the genotype of the mice. Grayscale images acquired in proprietary BioRad.pic format were imported into MetaMorph image analysis software (version 4.5r4; Universal Imaging, Downingtown, PA). The opened image was first calibrated for pixel size by applying a previously created calibration file. Segmented region areas, 40 x 40 pixel dimension, were applied to five randomly selected areas within the aortic media. A threshold encompassing an intensity range of 100250 grayscale values was applied to the segmented regions of interest. The mean integrated pixel values from the five areas per animal were calculated and data converted into a graphic bar chart for comparative analysis. The concentration of PAI-1 in protein extracted from VSMCs was assessed also with the use of an ELISA assay (MPAIKT-TOT kit; Innovative Research, Southfield, MI).
Vascular Lesion Compositional Analysis
Lipid was stained with oil red O (Pearse method). DAPI (4',6-diamidine-2-phenylindole dihydrochloride), a nucleic acid-binding fluorescent dye (Roche Diagnostics; Mannheim, Germany) was used to delineate cellularity. Stained sections were examined with an Olympus BX50 upright light microscope (Olympus America; Lake Success, NY) with an attached Optronics MagnaFire digital camera (Optical Analysis; Nashua, NH). Images were acquired with the use of MagnaFire software (version 2.1B).
Computer-assisted Quantitative Image Processing and Analysis
The captured digital images were transferred to a Dell 400 NT workstation for cropping and processing to yield 24-bit RGB images per section isolated on a white background as previously described (Taatjes et al. 2000). The processed images were opened in MetaMorph Image Analysis software for analysis. The images were opened as a group for the component of interest and calibrated for the objective lens used during image collection. Appropriate color thresholding parameters were applied.
Qualitative Image Analysis
An independent observer blinded with respect to mouse genotype and other analyses performed qualitative assessments. Cropped images that were used also for quantitative analysis described above were used for this purpose. A qualitative score with a scale of 1 to 5 describing the extent of cellularity and lipid content was assigned to each lesion. Qualitative analysis was performed by comparison of lesions with a set of reference images that had been analyzed quantitatively. A score of 1 reflected the lowest extent of cellularity or lipid content and 5 the greatest. Each increment reflected an approximate increase of 20%.
Statistical Analysis
Values are means ± SD. Significance, defined as p<0.05, was determined with the use of Student's t-tests.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
|
|
To determine which cells expressed PAI-1, multiple-labeling confocal scanning laser microscopy was performed. Consistent with our previous work, Figure 5 demonstrates that cells expressing -smooth muscle actin (indicative of VSMC origin) exhibited PAI-1 immunoreactivity (Taatjes et al. 1997
). By contrast, immunohistochemical expression of PAI-1 in parenchymal tissue of the lung, heart, liver, and kidney from transgene-positive mice was not increased (data not shown). PAI-1 activity in blood was similar in both members of seven pairs of transgene-positive (16 ± 3 AU/ml) and -negative (17 ± 3 AU/ml) littermates. A second SM22-PAI founder line exhibited similar increases in aortic expression of PAI-1. SM22-PAI mice did not exhibit phenotypic alterations with respect to longevity and reproduction. Macroscopic and microscopic examination of aortas did not demonstrate morphological changes.
|
|
|
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The objective of our study was to determine whether increased expression of PAI-1 altered the evolution of atheroma rather than a response to exogenous injury. This is because migration of VSMCs is likely to be pivotal during atherogenesis, whereas proliferation is potentially pivotal in response to exogenous injury. Nevertheless, our results are consistent with those of Carmeliet and colleagues, who found that mice in which expression of PAI-1 was increased exhibited decreased migration of VSMCs in response to electrically induced arterial mural injury (Carmeliet et al. 1997). By contrast, Lijnen and colleagues found that genetically increased expression of PAI-1 did not alter arterial VSMC content after severe electrical injury (Lijnen et al. 2004
). Zhu and colleagues found that neointimal formation was greater in ApoE/ that were wild-type with respect to expression of PAI-1 compared with ApoE/PAI-1/ mice when vascular injury was induced with ferric chloride (Zhu et al. 2001
). Another important distinction between our study and the previous studies is the use of mice in our study in which the expression of PAI-1 was affected selectively rather than ubiquitously.
Our results are consistent with observations in diverse systems and with diverse cell types (O'Grady et al. 1981; Saksela and Rifkin 1988
; Clowes et al. 1990
; Redmond et al. 2001
; Jackson and Reidy 1992
; Bendeck et al. 1994
; Stefansson and Lawrence 1996
; Werb et al. 1997
). Migration of human VSMC in vitro has been shown previously to be decreased by PAI-1 (Stefansson and Lawrence 1996
; Redmond et al. 2001
). Administration of a plasmin inhibitor, tranexamic acid, suppressed VSMC migration after injury of rat carotid arteries (Jackson and Reidy 1992
). Activation of matrix metalloproteinases by plasmin generated from the ECM was inhibited by PAI-1 (O'Grady et al. 1981
; Saksela and Rifkin 1988
; Clowes et al. 1990
; Bendeck et al. 1994
; Werb et al. 1997
), potentially constraining migration of many cell types.
Our results are consistent also with findings in patients that implicate PAI-1 in the potentiation of evolution of atherosclerotic plaques prone to rupture. Elevated concentrations of PAI-1 in blood are seen in patients with coronary artery disease, unstable angina, myocardial infarction, and stroke (Paramo et al. 1985; Juhan-Vague and Alessi 1993
; Padro et al. 1995
). Increased PAI-1 expression is evident in sections of atheroma (Schneiderman et al. 1992
; Lupu et al. 1995
; Padro et al. 1995
). In people with diabetes the incidence of myocardial infarction, generally a complication of plaque rupture, is increased fourfold (Uusitupa et al. 1990
). These patients have increased PAI-1 not only in blood but also in atheroma and arterial walls (Sobel et al. 1998
; Pandolfi et al. 2001
). Our results indicate that increased vessel wall expression of PAI-1 by VSMCs is likely to decrease their migration. Therefore, they are consistent with a predisposition towards the evolution of atherosclerotic plaques particularly prone to rupture in patients with increased VSMC expression of PAI-1 in vessel walls.
Diminution of increased intramural PAI-1 may favorably alter the evolution of atheroma with respect to cellular composition, thereby rendering them less vulnerable to rupture and less prone to precipitate an acute coronary syndrome. Diminution is an attractive target for prophylactic and therapeutic pharmacological intervention. Insulin sensitizers reduce elevated concentrations of PAI-1 in blood in patients with insulin resistance and those with type 2 diabetes mellitus. They attenuate evolution of atherogenesis, as judged from studies with duplex carotid ultrasound (Minamikawa et al. 1998; Koshiyama et al. 2001
). Increased PAI-1 may inhibit migration of VSMCs disproportionately to macrophage and T-lymphocyte migration, thereby accounting for the observed close correlation between increased predominance of macrophages and increased PAI-1 in atheroma from patients with unstable angina or acute myocardial infarction compared with those from patients with stable angina pectoris (Shindo et al. 2001
). A limitation of the current study is the absence of specific quantification of VSMCs and inflammatory cell content. Subsequent studies are planned to use confocal scanning laser microscopy to quantify the number of VSMCs, macrophages, and T-lymphocytes in vascular lesions of ApoE/ mice compared with ApoE/SM22-PAI+ mice.
In summary, our results indicate that overexpression of PAI-1 by VSMCs reduces their capacity to migrate through the ECM and to populate the neointima. Therefore, overexpression of PAI-1 during the development of atherosclerotic lesions does not necessarily change the size of the lesion but may promote formation of a plaque that is more prone to rupture. Accordingly, inhibition of vessel wall PAI-1 overexpression may facilitate evolution of atherosclerotic plaques that are less prone to rupture and precipitate acute coronary events.
![]() |
Footnotes |
---|
![]() |
Literature Cited |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA (1994) Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res 75:539545[Abstract]
Carmeliet P, Moons L, Linjen R, Janssens S, Lupu F, Collen D, Gerard R (1997) Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation. Circulation 96:31803191
Clowes A, Clowes M, Au Y, Reidy M, Belin D (1990) Smooth muscle cells express urokinase during mitogenesis and tissue type plasminogen activator during migration in injured rat carotid artery. Circ Res 67:6167[Abstract]
Davies MJ, Thomas AC (1985) Plaque fissuringthe cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br Heart J 53:363373[Medline]
Falk E, Shah PK, Fuster V (1995) Coronary plaque disruption. Circulation 92:657671
Jackson CL, Reidy MA (1992) The role of plasminogen activator in smooth muscle cell migration after injury. Ann NY Acad Sci 667:141150[Abstract]
Juhan-Vague I, Alessi MC (1993) Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost 70:138143[Medline]
Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y (2001) Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 86:34523456
Libby P (1995) Molecular basis of the acute coronary syndromes. Circulation 91:28442850
Lijnen HR, Van Hoef B, Umans K, Collen D (2004) Neointimal formation and thrombosis after vascular injury in transgenic mice overespressing plasminogen activator inhibitor-1 (PAI-1). J Thromb Haemost 2:1620[CrossRef][Medline]
Lupu F, Heim D, Bachman F, Hurni M, Kakkar V, Kruithof K (1995) Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 15:14441455
Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H (1998) Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 83:18181820
O'Grady RL, Upfold RL, Stephens RW (1981) Rat mammary carcinoma cells secrete active collagenase and activate latent enzyme in the stroma via plasminogen activator. Int J Cancer 28:509515[Medline]
Padro T, Emeis J, Steins M, Schmid K, Kienast J (1995) Quantification of plasminogen activators in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease. Arterioscler Thromb Vasc Biol 15:893902
Pandolfi A, Cetrullo D, Polishuck R, Alberta MM, Calafiore A, Pellegrini G, Vitacolonna E, et al. (2001) Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects. Arterioscler Thromb Vasc Biol 8:13781382
Paramo JA, Colucci M, Collen D (1985) Plasminogen activator inhibitor in the blood of patients with coronary artery disease. BMJ 291:573577[Medline]
Redmond EM, Cullen JP, Cahill PA, Sitzmann JV, Stefansson S, Lawrence DA, Okada SS (2001) Endothelial cells inhibit flow-induced smooth muscle cell migration: role of plasminogen activator inhibitor-1. Circulation 103:597603
Rincón M, Enslen H, Raingeaud J, Recht M, Zapton T, Su MS, Penix LA, Davis RJ, Flavell RA (1998) Interferon-gamma expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway. EMBO J 17:28172829
Ross R (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362:801809[CrossRef][Medline]
Saksela O, Rifkin DB (1988) Cell associated plasminogen activation: Regulation and physiologic functions. Ann Rev Cell Biol 4:93126.[CrossRef]
Schneiderman J, Sawdey SM, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Luskutoff DJ (1992) Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 89:69987002[Abstract]
Shindo J, Ishibashi T, Kijima M, Nakazato K, Nagata K, Yokoyama K, Hirosaka A, et al. (2001) Increased plasminogen activator inhibitor-1 and apolipoprotein(a) in coronary atherectomy specimens in acute coronary syndromes. Coron Artery Dis 12:573579[CrossRef][Medline]
Sjoland H, Eitzman D, Gordon D, Westrick R, Nabel E, Ginsberg D (2000) Atherosclerosis progression in LDL receptor deficient and apolipoprotein E deficient mice is independent of genetic alterations in plasminogen activator inhibitor 1. Arterioscler Thromb Vasc Biol 20:846852
Sobel BE (1999) Increased plasminogen activator inhibitor-1 and vasculopathy: a reconcilable paradox. Circulation 99:24962498
Sobel BE, Taatjes DJ, Schneider DJ (2003) Intramural plasminogen activator inhibitor type-1 (PAI-1) and coronary atherosclerosis. Arterioscler Thromb Vasc Biol 23:19791989.
Sobel BE, Woodcock-Mitchell J, Schneider D, Holt R, Marutsuka K, Gold H (1998) Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients. Circulation 97:22132220
Solway J, Seltzer J, Samaha FF, Kim S, Alger LE, Niu Q, Morrisey EE, et al. (1995) Structure and expression of a smooth muscle cell-specific gene, SM22. J Biol Chem 270:1346013469
Stefansson S, Lawrence DA (1996) The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature 383:441443[CrossRef][Medline]
Taatjes DJ, Palmer CJ, Pantano C, Buder-Hoffmann S, Cummins A, Mossman BT (2001) Laser-based microscopic approaches: application to cell signaling in environmental lung disease. BioTechniques 31:880895[Medline]
Taatjes DJ, Wadsworth M, Absher PM, Sobel BE, Schneider DJ (1997) Immunoelectron microscopic localization of plasminogen activator imhibitor type 1 (PAI-1) in smooth muscle cells from morphologically normal and atherosclerotic human arteries. Ultrastruct Pathol 21:527536[Medline]
Taatjes DJ, Wadsworth MP, Schneider DJ, Sobel BE (2000) Improved quantitative characterization of atherosclerotic plaque composition with immunohistochemistry, confocal fluorescence microscopy, and computer-assisted image analysis. Histochem Cell Biol 113:161173[CrossRef][Medline]
Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K (1990) 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin levels, and abnormalities in lipoprotein composition in non-insulin dependent diabetic and non-diabetic subjects. Circulation 82:2736[Abstract]
Werb Z, Mainardi C, Vater CA, Harris ED (1997) Endogenous activation of latent collagenase by rheumatoid synovial cells: evidence for a role of plasminogen activator. N Engl J Med 296:10171023
Zhu Y, Farrehi PM, Fay WP (2001) Plasminogen activator inhibitor type 1 enhances neointima formation after oxidative vascular injury in atherosclerosis-prone mice. Circulation 103:31053110